Total trials
116
Active
8
Phase 3
11
Total enrollment
272,524
Pipeline matrix
Showing 20 of 20 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dihydroartemisinin-piperaquine | — | — | — | — | 2 | ||
| yellow fever vaccine | — | — | — | — | 2 | ||
| Novel Oral Polio Vaccine Type 1 | — | — | — | — | 2 | ||
| Novel oral poliomyelitis vaccine type 1 | — | — | — | — | — | 1 | |
| Novel oral poliomyelitis vaccine type 2 | — | — | — | — | — | 1 | |
| Novel oral poliomyelitis vaccine type 3 | — | — | — | — | — | 1 | |
| Bivalent Oral Poliomyelitis Vaccine | — | — | — | — | — | 1 | |
| Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine | — | — | — | — | — | 1 | |
| Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 | — | — | — | — | — | 1 | |
| Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine | — | — | — | — | — | 1 | |
| Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 | — | — | — | — | — | 1 | |
| Novel Oral Polio Vaccine Type 2 | — | — | — | — | — | 1 | |
| R21 Matrix-M (R21/MM) Malaria Vaccine | — | — | — | — | — | 1 | |
| Hexavalent Vaccine | — | — | — | — | — | 1 | |
| Pneumococcal Polysaccharide Conjugate Vaccine | — | — | — | — | — | 1 | |
| Rotavirus, Live Attenuated (Oral) Vaccine | — | — | — | — | — | 1 | |
| Measles and Rubella Vaccine | — | — | — | — | — | 1 | |
| Meningococcal (A, C, Y, W, X) polysaccharide conjugate vaccine | — | — | — | — | — | 1 | |
| Typhoid Conjugate vaccine | — | — | — | — | — | 1 | |
| long-acting depot buprenorphine | — | — | — | — | — | 1 |
Next readouts
- 2025-01-24
- 2026-05-15
- 2026-12-28
- 2026-12-31
- 2027-03-20
- 2027-09-27
- 2027-12-15
Top conditions
- Malaria18
- Influenza11
- Diarrhea8
- Poliomyelitis6
- G6PD Deficiency4
- Visceral Leishmaniasis3
- Pneumonia, Pneumococcal3
- Japanese Encephalitis3
Frequently asked questions about PATH
- How many clinical trials does PATH have on ClinicalTrials.gov?
- PATH is listed as the lead sponsor on 116 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of PATH's trials are in Phase 3?
- 11 of PATH's trials are in Phase 3, spread across 20 active drug programs.
- What therapeutic areas does PATH focus on?
- PATH's most-studied conditions on ClinicalTrials.gov are Malaria, Influenza, Diarrhea, Poliomyelitis, G6PD Deficiency.
- When are PATH's next clinical trial readouts?
- PATH has 7 upcoming primary-completion readouts tracked here; the soonest is “Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia”, expected around 2025-01-24.